Acro Biomedical (ACBM) Enterprise Value (2018 - 2026)

Acro Biomedical has reported Enterprise Value for 9 years, with the latest figure at $1.8 million in Q2 2026.

• On a quarterly basis, Enterprise Value changed N/A year-over-year to $1.8 million in Q2 2026; TTM through Jun 2026 was $1.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $951102.0, changed N/A from the prior year.
• Enterprise Value was $1.8 million for Q2 2026 at Acro Biomedical, up from $1.2 million in the prior quarter.
• The five-year high for Enterprise Value was $270.2 million in Q4 2022, with the low at $1.2 million in Q4 2025.
• Average Enterprise Value over 5 years is $120.0 million, with a median of $79.5 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value soared 101.15% in 2022, then plunged 97.78% in 2023.
• Over 5 years, Enterprise Value stood at $270.2 million in 2022, then slumped by 97.78% to $6.0 million in 2023, then fell by 0.01% to $6.0 million in 2024, then sank by 80.07% to $1.2 million in 2025, then surged by 50.21% to $1.8 million in 2026.
• The last three Enterprise Value figures came in at $1.8 million (Q2 2026), $1.2 million (Q4 2025), and $6.0 million (Q2 2024), per Business Quant data.